140 related articles for article (PubMed ID: 35301651)
21. Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.
Jiao R; Luo H; Xu W; Ge H
Onco Targets Ther; 2019; 12():6023-6032. PubMed ID: 31551657
[TBL] [Abstract][Full Text] [Related]
22. Genetic and molecular characterization of metabolic pathway-based clusters in esophageal squamous cell carcinoma.
Wang Z; Zhang Y; Yang X; Zhang T; Li Z; Zhong Y; Fang Y; Chong W; Chen H; Lu M
Sci Rep; 2024 Mar; 14(1):6200. PubMed ID: 38486026
[TBL] [Abstract][Full Text] [Related]
23. Unraveling the puzzle: efficacy of PD-L1 inhibitors in esophageal squamous cell carcinomas with low PD-L1 expression-a comprehensive overview of challenges and limitations.
El Khatib S; Saeed A
Transl Cancer Res; 2023 Dec; 12(12):3245-3248. PubMed ID: 38192985
[No Abstract] [Full Text] [Related]
24. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
25. Cancer-associated fibroblasts: An emerging target against esophageal squamous cell carcinoma.
Qiu L; Yue J; Ding L; Yin Z; Zhang K; Zhang H
Cancer Lett; 2022 Oct; 546():215860. PubMed ID: 35948121
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells.
Yi YW
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835116
[TBL] [Abstract][Full Text] [Related]
27. Cigarette smoke-promoted increases in osteopontin expression attract mesenchymal stem cell recruitment and facilitate lung cancer metastasis.
Jiang YJ; Chao CC; Chang AC; Chen PC; Cheng FJ; Liu JF; Liu PI; Huang CL; Guo JH; Huang WC; Tang CH
J Adv Res; 2022 Nov; 41():77-87. PubMed ID: 36328755
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wang R; Liu S; Chen B; Xi M
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291954
[TBL] [Abstract][Full Text] [Related]
29. A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response.
Sharma U; Murmu M; Barwal TS; Tuli HS; Jain M; Prakash H; Kaceli T; Jain A; Bishayee A
Curr Oncol; 2022 Mar; 29(4):2326-2349. PubMed ID: 35448163
[TBL] [Abstract][Full Text] [Related]
30. Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: a critical role for exosomes.
Wang B; Cheng D; Ma D; Chen R; Li D; Zhao W; Fang C; Ji M
Cell Commun Signal; 2024 Jan; 22(1):21. PubMed ID: 38195554
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatments for resectable carcinoma of the esophagus.
Leowattana W; Leowattana P; Leowattana T
World J Gastroenterol; 2023 Aug; 29(30):4628-4641. PubMed ID: 37662861
[TBL] [Abstract][Full Text] [Related]
32. Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells.
Doukuni R; Kobori T; Tanaka C; Tameishi M; Urashima Y; Ito T; Obata T
J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807113
[TBL] [Abstract][Full Text] [Related]
33. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
Tsutsumi S; Saeki H; Nakashima Y; Ito S; Oki E; Morita M; Oda Y; Okano S; Maehara Y
Cancer Sci; 2017 Jun; 108(6):1119-1127. PubMed ID: 28294486
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-β1-induced epithelial-mesenchymal transition in human esophageal squamous cell carcinoma via the PTEN/PI3K signaling pathway.
Zhang HY; Wang ZQ; Li YY; Wang F; Zeng QR; Gao Y; Xuan XY; Li SS
Oncol Rep; 2014 Nov; 32(5):2134-42. PubMed ID: 25175594
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
Liu Z; Sun L; Cai L; Guo M; Xu G; Liu S; Zheng G; Wang Q; Lian X; Feng F; Zhang H
Postgrad Med J; 2022 Dec; 98(1166):948-957. PubMed ID: 34253568
[TBL] [Abstract][Full Text] [Related]
36. Perioperative immunotherapy for esophageal squamous cell carcinoma.
Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
[TBL] [Abstract][Full Text] [Related]
37. Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.
Qiu R; Wang W; Li J; Wang Y
Mol Biol Rep; 2022 Jul; 49(7):6633-6645. PubMed ID: 35301651
[TBL] [Abstract][Full Text] [Related]
38. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
